I think it is important to separate something like oncology - which I don't think will be materially affected unless there really is a drain on FDA resources - with public health, with which we truly are playing with fire I think oncology gets approved just as fast as before trump/rfk, I think conditions that are milder for which there are existing alternatives may require more safety and rigor (although not totally clear yet), but vaccines and pandemic preparedness is the real legitimate concern So as an investment board that is my opinion on where the risk (and lack of risk) lies
Market Data 
Markets 
AI
